Table 2. Univariate and multivariate survival analyses.
| Variables | 5-year CSS | Univariate analysis | Multivariate analysis† | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| Diagnosis year | ||||||
| 2004–2008 | 57.9% | Reference | Reference | |||
| 2009–2014 | 57.5% | 0.99 (0.85–1.17) | 0.9369 | 0.85 (0.72–1.01) | 0.0588 | |
| Age, years | ||||||
| 18–49 | 66.6% | Reference | Reference | |||
| 50–69 | 65.5% | 1.12 (0.86–1.45) | 0.4039 | 1.10 (0.84–1.43) | 0.5011 | |
| 70–79 | 50.0% | 1.73 (1.30–2.29) | 0.0001 | 1.48 (1.10–2.00) | 0.0100 | |
| ≥80 | 38.5% | 2.55 (1.95–3.66) | <0.0001 | 2.62 (1.92–3.58) | <0.0001 | |
| Marital status | ||||||
| Married | 64.4% | Reference | Reference | |||
| Single | 60.6% | 1.20 (0.95–1.51) | 0.1232 | 1.05 (0.83–1.34) | 0.6746 | |
| Divorced/separated | 56.6% | 1.27 (1.00–1.61) | 0.0469 | 1.26 (0.99–1.61) | 0.0595 | |
| Widowed | 44.1% | 1.81 (1.49–2.19) | <0.0001 | 1.02 (0.82–1.27) | 0.8664 | |
| Race | ||||||
| White | 58.6% | Reference | Reference | |||
| Black | 51.7% | 1.25 (1.01–1.54) | 0.0386 | 1.23 (0.99–1.53) | 0.0618 | |
| Other | 61.3% | 0.85 (0.61–1.19) | 0.3404 | 0.81 (0.57–1.14) | 0.2313 | |
| Unknown | 75.0% | 0.48 (0.07–3.41) | 0.4626 | 0.51 (0.07–3.64) | 0.5000 | |
| Pathological grading | ||||||
| I | 61.7% | Reference | Reference | |||
| II | 61.0% | 0.97 (0.70–1.35) | 0.8644 | 0.94 (0.67–1.30) | 0.6920 | |
| III | 55.1% | 1.28 (0.93–1.76) | 0.1260 | 1.02 (0.73–1.40) | 0.9305 | |
| IV | 36.2% | 1.82 (1.82–2.91) | 0.0128 | 1.00 (0.62–1.62) | 0.9947 | |
| Unknown | 58.6% | 1.11 (0.80–1.53) | 0.5408 | 0.76 (0.54–1.08) | 0.1240 | |
| Histology | ||||||
| Squamous cell carcinoma | 63.6% | Reference | Reference | |||
| Adenocarcinoma | 59.3% | 0.86 (0.69–1.08) | 0.1925 | 1.00 (0.79–1.26) | 0.9864 | |
| Melanoma | 19.2% | 2.70 (2.01–3.63) | <0.0001 | 4.35 (3.06–6.18) | <0.0001 | |
| Sarcoma | 58.8% | 1.19 (0.65–2.16) | 0.5740 | 1.98 (1.06–3.72) | 0.0331 | |
| Other | 47.2% | 1.26 (0.87–1.81) | 0.2158 | 1.42 (0.97–2.10) | 0.0740 | |
| TNM stage | ||||||
| I | 76.4% | Reference | Reference | |||
| II | 61.9% | 1.74 (1.37–2.21) | <0.0001 | 1.77 (1.37–2.30) | <0.0001 | |
| III | 53.3% | 2.33 (1.81–2.09) | <0.0001 | 2.28 (1.74–2.99) | <0.0001 | |
| IV | 22.5% | 6.17 (4.93–7.73) | <0.0001 | 5.43 (4.24–6.96) | <0.0001 | |
| Tumor size | ||||||
| Less than 4 cm | 71.8% | Reference | Reference | |||
| Greater than 4 cm | 45.4% | 2.49 (2.04–3.04) | <0.0001 | 1.62 (1.31–2.01) | <0.0001 | |
| Unknown | 51.0% | 2.14 (1.75–2.61) | <0.0001 | 1.60 (1.31–1.97) | <0.0001 | |
| Surgery | ||||||
| No | 48.9% | Reference | Reference | |||
| Yes | 72.1% | 0.43 (0.36–0.51) | <0.0001 | 0.46 (0.38–0.57) | <0.0001 | |
| Unknown | 60.6% | 0.67 (0.25–1.80) | 0.4296 | 0.66 (0.24–1.79) | 0.4132 | |
| Radiation | ||||||
| No | 52.5% | Reference | Reference | |||
| Yes | 59.4% | 0.69 (0.58–0.82) | <0.0001 | 0.52 (0.43–0.63) | <0.0001 | |
†, model adjusted for year of diagnosis, marital status, race, tumor size, grade, surgery, and radiation.